These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31543677)

  • 1. Crosstalk network among multiple inflammatory mediators in liver fibrosis.
    Zhangdi HJ; Su SB; Wang F; Liang ZY; Yan YD; Qin SY; Jiang HX
    World J Gastroenterol; 2019 Sep; 25(33):4835-4849. PubMed ID: 31543677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
    Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
    World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 15th International Symposium on Cells of the Hepatic Sinusoid, 2010.
    DeLeve LD; Jaeschke H; Kalra VK; Asahina K; Brenner DA; Tsukamoto H
    Liver Int; 2011 Jul; 31(6):762-72. PubMed ID: 21645207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic inflammation and progressive liver fibrosis in chronic liver disease.
    Czaja AJ
    World J Gastroenterol; 2014 Mar; 20(10):2515-32. PubMed ID: 24627588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.
    An P; Wei LL; Zhao S; Sverdlov DY; Vaid KA; Miyamoto M; Kuramitsu K; Lai M; Popov YV
    Nat Commun; 2020 May; 11(1):2362. PubMed ID: 32398673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages: master regulators of inflammation and fibrosis.
    Wynn TA; Barron L
    Semin Liver Dis; 2010 Aug; 30(3):245-57. PubMed ID: 20665377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
    Khanam A; Saleeb PG; Kottilil S
    Cells; 2021 May; 10(5):. PubMed ID: 34064375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 2 signaling in liver pathophysiology.
    Getachew A; Hussain M; Huang X; Li Y
    Life Sci; 2021 Nov; 284():119941. PubMed ID: 34508761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases.
    Oliveira SC; Delpino MV; Giambartolomei GH; Quarleri J; Splitter G
    Front Immunol; 2020; 11():1760. PubMed ID: 32849629
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting cell-intrinsic metabolism for antifibrotic therapy.
    Gilgenkrantz H; Mallat A; Moreau R; Lotersztajn S
    J Hepatol; 2021 Jun; 74(6):1442-1454. PubMed ID: 33631228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver regeneration and inflammation: from fundamental science to clinical applications.
    Campana L; Esser H; Huch M; Forbes S
    Nat Rev Mol Cell Biol; 2021 Sep; 22(9):608-624. PubMed ID: 34079104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of hepatocyte cell division leads to liver inflammation and fibrosis.
    Dewhurst MR; Ow JR; Zafer G; van Hul NKM; Wollmann H; Bisteau X; Brough D; Choi H; Kaldis P
    PLoS Genet; 2020 Nov; 16(11):e1009084. PubMed ID: 33147210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities.
    Binatti E; Gerussi A; Barisani D; Invernizzi P
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of macrophage phenotype to treat liver fibrosis-Current approaches and future possibilities.
    Strickland JD; Copple BL
    Adv Pharmacol; 2021; 91():213-228. PubMed ID: 34099109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent insights of the role and signalling pathways of interleukin-34 in liver diseases.
    Al-Shaebi F; Wenzhang L; Hezam K; Almezgagi M; Wei L
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107023. PubMed ID: 33129098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.
    Roehlen N; Crouchet E; Baumert TF
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathobiology and therapeutic targets related to cytokines in liver diseases.
    He Y; Hwang S; Ahmed YA; Feng D; Li N; Ribeiro M; Lafdil F; Kisseleva T; Szabo G; Gao B
    Cell Mol Immunol; 2021 Jan; 18(1):18-37. PubMed ID: 33203939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LC3-associated phagocytosis in myeloid cells, a fireman that restrains inflammation and liver fibrosis, via immunoreceptor inhibitory signaling.
    Wan J; Weiss E; Ben Mkaddem S; Mabire M; Choinier PM; Thibault-Sogorb T; Hegde P; Bens M; Broer L; Gilgenkrantz H; Moreau R; Saveanu L; Codogno P; Monteiro RC; Lotersztajn S
    Autophagy; 2020 Aug; 16(8):1526-1528. PubMed ID: 32434445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special Issue on "Cellular and Molecular Mechanisms Underlying the Pathogenesis of Hepatic Fibrosis".
    Weiskirchen R
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease.
    Fang H; Jiang L
    Front Immunol; 2021; 12():687291. PubMed ID: 34489936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.